T
Tandem Labs
Leading bioanalytical contract research organization (cro) specializing in advanced mass spectrometry
About Tandem Labs
Tandem Labs positions itself as a luxury supplement division of Tandem Regenerative, focusing on pharmacy-grade formulations. The company's stated vision is to apply the exacting standards of pharmaceutical care to the world of supplementation.
The business model centers on creating and selling high-end supplements designed specifically to complement and enhance the effects of peptide and GLP-1 therapies. These products aim to deliver tangible results by blending scientifically researched ingredients in precise dosages. The target market includes individuals utilizing advanced peptide and GLP-1 protocols who are seeking to optimize their health outcomes.
Tandem Labs' product line consists of targeted solutions formulated to support metabolic health, improve recovery times, enhance cognitive function, and promote graceful aging. The company emphasizes the quality and purity of its offerings, partnering exclusively with U.S.-based manufacturers that adhere to Good Manufacturing Practice (GMP) standards. This ensures the potency and consistency of every product batch. The core of their strategy is to provide intentional, elevated supplementation tailored to a specific health-conscious lifestyle, working in synergy with the body's natural processes to amplify the impact of sophisticated therapies.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1995
- Headquarters
- Millcreek, United States
- Employees
- 81
- Open positions
- None listed
- Dealroom signal
- 33.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Biotech and Pharma, Hard Tech, medical testing, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jan 2008 | $0 | — | LabCorp | — |
| SERIES A✓Equity / VC | Jun 2005 | $19M | $75M | DW Healthcare Partners | — |
Growth signals
Latest recorded traffic for Tandem Labs is 110 monthly website visits, up 266.7% over the last three months. Tandem Labs's team declined 12.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
DW Healthcare Partners
Other known investors1 additional known investor
LabCorp
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tandem Labs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tandem Labs’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.